Icosavax, Inc. (ICVX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ICVX Stock Price Chart Interactive Chart >
ICVX Price/Volume Stats
| Current price | $10.23 | 52-week high | $49.99 |
| Prev. close | $8.16 | 52-week low | $4.00 |
| Day low | $8.02 | Volume | 256,287 |
| Day high | $10.67 | Avg. volume | 300,549 |
| 50-day MA | $8.52 | Dividend yield | N/A |
| 200-day MA | $20.74 | Market Cap | 406.44M |
Icosavax, Inc. (ICVX) Company Bio
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Latest ICVX News From Around the Web
Below are the latest news stories about Icosavax Inc that investors may wish to consider to help them evaluate ICVX as an investment opportunity.
Pan-COVID-19 Vaccine Could Be a Solution to End the Pandemic; Jefferies Taps 2 Stocks to BenefitThe coronavirus pandemic is still making headlines; it’s presenting us with a stubborn problem, one that won’t go away and resists the normal weapons that modern medicine has brought against it. The result is a sense of fatalism, that we may as well just get used to corona. No one likes that idea. The medical researchers, especially, aren’t liking that, and they are working to bring new techniques to bear on the virus. Among the more promising is the ‘pan-COVID’ approach, the development of a va |
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Icosavax (ICVX)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Icosavax (ICVX – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company's shares closed last Friday at $84.25. According to TipRanks. |
Icosavax outlines anticipated milestones for 2022No summary available. |
Icosavax Provides Corporate Update and Anticipated Milestones for 2022SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS). Icosavax has exercised its o |
Icosavax Appoints Dr. John Shiver to Board of Directors- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases -SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research an |
ICVX Price Returns
| 1-mo | 33.90% |
| 3-mo | -41.88% |
| 6-mo | -62.87% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -55.29% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...